




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : B23K 26/00		A1	(11) International Publication Number: WO 94/01239
			(43) International Publication Date: 20 January 1994 (20.01.94)
(21) International Application Number: PCT/US93/06197 (22) International Filing Date: 30 June 1993 (30.06.93) (30) Priority data: 909,892 7 July 1992 (07.07.92) US (60) Parent Application or Grant (63) Related by Continuation US Filed on 909,892 (CIP) 7 July 1992 (07.07.92) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only): ROY, Stephen [US/US]; 39 W. School Street, Westfield, MA 01085 (US). (74) Agent: BIGLEY, Francis, P.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: HIGH SPEED PROCESS FOR PREPARING ORIFICES IN PHARMACEUTICAL DOSAGE FORMS



(57) Abstract

A laser drilling process capable of producing a plurality of holes in a pharmaceutical dosage form, at high speed, is presented. The process utilizes a digital laser marking system (DIGIMARK™ variable marking system) (22) to produce an unlimited number of holes through the surface or coating of a dosage form (12), at rates up to 100,000 units or more per hour.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	CN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

- 1 -

TITLE OF THE INVENTIONHIGH SPEED PROCESS FOR PREPARING ORIFICES IN
PHARMACEUTICAL DOSAGE FORMS5 BACKGROUND OF THE INVENTION

There is a need within the pharmaceutical industry to produce an opening in the surface of many types of dosage forms. For example, certain controlled release devices rely on an opening which extends from outside the device, through an outer coating or housing and into the core of the device, as a means of releasing material stored within the core to the environment of use.

Often these controlled release devices rely on osmotic pressure, diffusion or surface hydration to deliver the contents of the core through the opening.

15 U.S. Patent 4,088,864 reported the use of a laser to produce outlet passage-way in the walls of pills which dispense their contents osmotically. This technique comprised moving the pills in succession along a predetermined path at a predetermined velocity; tracking the moving pills seriatim with a laser of a wavelength which is absorbable by the walls. The laser beam dimensions at the wall, the laser power and the firing duration were such as to cause the laser beam to heat and pierce the wall and produce an outlet passageway 4 to 2000 microns in diameter through the wall and into the device core.

25 There is further a need to produce dosage forms containing multiple holes through the dosage form and into the core of the dosage form. Application 07/815,304, filed December 28, 1991, for example, relies in part on multiple holes drilled through a water impermeable membrane. The holes expose multiple portions of the dosage form core to the environment of use, allowing for delivery of the drug stored within the core.

30 Jain, N.K. and Naik S.U., J. Pharm Sci., 73, 1806-1811 (1984), have reported on the use of a laser to drill holes in capsules. To vary the number of pores, the capsule was mounted on a linear drive and moved at a speed of 2 mm/sec. By changing the laser frequency

- 2 -

and keeping the power and pulse width constant 25 to 100 pores were drilled on the body of the capsule shell.

Technology required to produce multiple patterns of openings through the dosage form shell or coating without repositioning of the dosage form has previously not been available. A process which provides for rapid through-put of dosage forms, capable of providing such a pattern of openings, without such manipulation is desirable.

Recently, laser systems which employ a linear array of individual laser tubes have been developed. These systems allow the user to pulse only those lasers needed so as to produce a linear array of laser beams. In U.S. Patent 5,049,721, such a system was used to provided markings in an outer jacket of repetitively spaced sections along the length of a moving cable. As the cable was moved along, the lasers were pulsed, via a computer program, to produce the letters and symbols.

Applicants have found a novel use for this technology in the chemical delivery field, in that multiple arrays of holes can be drilled in dosage form devices more rapidly and precisely than heretofore thought possible.

SUMMARY OF THE INVENTION

The present invention is directed to a novel process for producing a plurality of apertures in a chemical dosage form using a digital laser marking system. The chemical dosage form is conveyed to the laser stage using any conventional means. Once in position, any of the plurality of tubes of the digital laser marking system can be pulsed individually or in parallel. The pulse width, the composition of the dosage form and the speed which the tablet travels through the stage, determines the depth through which the laser burns and the shape of the aperture. Since the laser tubes are individually controlled, a desired pattern of apertures can be produced on the dosage form. By varying the internal stroke time, a two dimensional array of apertures may be reproducibly drilled on the dosage forms. Using mirrors and other

- 3 -

optical devices, multiple faces of the dosage form may be drilled simultaneously.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1, is a side view of the process wherein dosage forms are continuously moved through the stage below the digital laser marking system.

 Figure 2, is a plan view of an apertured dosage form containing 21 apertures.

10 Figure 3, is a plan view of an apertured dosage form containing four circular apertures.

 Figure 4, is a plan view of an apertured dosage form containing a 4 x 5 array of circular apertures.

15 Figure 5, is a plan view of an apertured dosage form containing three different linear arrays of apertures.

DETAILED DESCRIPTION OF THE DRAWINGS

20 In Figure 1, dosage forms (13) are delivered to a moving conveyer system (10) from a storage container (11). The moving conveyer system (10) transports the dosage form into and out of the laser stage (13) of a digital laser marking system (14). The apertured dosage forms are collected in a final storage container (15).

25 U.S. Patent No. 4,720,618 and U.S. Patent No. 4,727,235 teach the laser marker (22) of Fig. 1 and hereby are incorporated by reference. The laser marker includes a computer (16), a monitor (19) with a keyboard (20), a laser interface circuit (17), seven radio frequency amplifiers (18), a direct current power supply (21) and a laser head (14) with a beam delivery tube and a lens. The laser head (14) includes seven carbon dioxide lasers which are excited by radio
30 frequency energy at a frequency of 27 mega hertz to a nominal power of 20 watts. The output beams of the seven lasers are directed through the beam delivery tube via mirrors onto the lens which focuses the output beams onto a drilling area. The output of the seven carbon dioxide lasers are focused by the lens to form a seven dot-high vertical

- 4 -

column of beams. Since the surface of the dosage form (12) moves transversely with respect to the vertical column it is possible to create a 7 by n dot array, (where n is the number of columns of dots in the array). Designs may be generated by selectively controlling each laser and the velocity of the dosage form through the laser stage (13). The keyboard (20) of the monitor (19) permits the operator to communicate with the computer (16) in order to enter data and alter the operation of the laser interface circuit (17). The radio frequency energy for exciting the lasers is generated by the radio frequency amplifiers (18) which are located in a control console. There is one radio frequency amplifier (18) for each laser. The radio frequency amplifiers (18) are controlled by digital signals from the computer (16) via the laser interface circuit (17). Each laser is controllable by a separate signal which turns the laser on or off depending on the desired aperture array.

Referring to Fig. 3 in conjunction with Fig. 1, the apertures (30) are a plurality of drilled openings which pierce the outer surface of the dosage form. If four of the carbon dioxide lasers are pulsed once while a dosage form is within the laser stage (13) a single linear array of four apertures appear in the dosage form. However, if four of the carbon dioxide lasers are pulsed five times while the dosage form moves through the laser stage (13) then the dosage form depicted in Fig. 4 results, containing a 4 x 5 array of apertures.

The speed with which the dosage form moves through the laser stage and the pulse width determine the shape of the aperture. As Fig. 5 shows, near circular apertures (40) result from short pulse width and reduced velocity through the laser stage (13). More elongated, oval apertures (41) may be obtained using longer pulse widths and faster movement through the laser stage (13).

Since the seven carbon dioxide lasers can be independently pulsed, arrays such as that depicted in Fig. 5 can result. That is, combinations of different types of apertures may be produced on the same dosage form.

The distance between the linear arrays is a function of the internal stroke time of the laser and the velocity of the dosage form

- 5 -

through the laser stage. Shorter internal stroke times or faster dosage form velocity or both result in reduced distance between the linear arrays.

5 The depth of the apertures in the dosage form is a function of the pulse width, velocity and the composition of the dosage form. Aperture depth of from about 20 microns to about 1 cm may be required depending upon the application.

10 In alternative embodiments of the present invention, other laser marking systems may be used to produce the apertures in the dosage form. The laser marker of the preferred embodiment includes seven carbon dioxide lasers. U.S. Patent 4,636,043, teaches another laser marker which utilizes a laser scanner to mark items. U.S. Patent 4,024,545, teaches yet another laser marker for inscribing markings, such as alphanumeric characters and symbols, in the outer surface layer of an article in accordance with predetermined information. Other lasers, including, but not being limited to, an argon laser, another carbon dioxide laser, a neodymium:YAG laser, an erbium:YAG laser, and an excimer laser, may be used in each of these laser markers so long as the laser marker is able to produce apertures in the dosage form (12).

15 From the foregoing, it can be seen that a laser marking apparatus which provides an array of apertures in a moving dosage form has been described.

20 It should be noted that the sketches are not drawn to scale and that distance between the figures are not to be considered significant.

DESCRIPTION OF THE INVENTION

25 The invention concerns a novel process for producing a dosage form having a plurality of apertures in its outside surface, using a digital laser marking system focused at a laser stage, the steps comprising:

- 30 (a) moving the dosage form into the laser stage of the digital laser marking system;

- 6 -

- (b) pulsing the digital laser marking system to energize those laser tubes needed to drill the desired apertures along a linear array on the dosage form;
- (c) moving the dosage form forward at the laser stage and pulsing the digital laser marking system to produce an additional linear array of artures as required;
- (d) removing the dosage form from the laser stage.

By "dosage form" is meant any device capable of delivering a chemical which requires a plurality of apertures through which the chemical may move into the environment of use. The environment of use is not limited. It may be of a biological nature, for example pharmaceutical drug delivery, or industrial use such as water or air treatment, or any other area in need of delivery of a chemical through a plurality of apertures. The term "dosage form" further includes but is not limited to items such as coated or uncoated tablets, capsules, lozenges, boluses, pills, wafers, disks, expandable devices, patches, suppositories, collars, pellets, controlled release devices, slow release devices, room freshener devices, water treatment delivery devices, and other chemical delivery devices.

By "laser stage" is meant the area accessible to the laser beams where drilling may occur. This area may be directly below the laser tubes or if suitable optics are utilized may be remotely located from the bottom of the laser tubes.

By "apertures" is meant holes or openings starting at the surface of the dosage form and extending into the dosage form to a predetermined depth within the dosage form. Alternatively, the apertures may go completely through the dosage form. The apertures may pierce the coating of a dosage form thus exposing the interior of the dosage form to the environment of use. Additionally, the apertures may provide an exit means for the chemical stored inside a dosage form to be expelled under osmotic pressure, diffusion or surface hydration.

The apertures may be arrayed closely so as to produce perforations which define an area of the dosage form which is to be

- 7 -

discarded prior to use or expelled during use. Any number of apertures may be contained within the array. When boluses and other large dosage forms are prepared, $m \times n$ array containing from 1 to 1000 or more apertures for each member of the array may be needed. Thus, it would not be outside this invention for a dosage form to contain 1000 columns of apertures each containing 1000 apertures (i.e. $m = 1000$ and $n = 1000$). For most larger dosage forms, from 5 to 1000 apertures are drilled in one or more faces of the dosage form.

When other smaller dosage forms are prepared, $m \times n$ arrays containing from 10 to 50 apertures may be required. Thus, it would be within this invention for a dosage form to contain 5 columns of 10 apertures each. (i.e. $m = 5$ and $n = 10$) Further, the apertures may be arrayed in a manner which produces a pattern which identifies the dosage form prior to or during use.

The digital laser marking system may be used either alone or in conjunction with a printing means to inscribe alpha-numeric characters or other symbols on the dosage form using technology such as that described in U.S. Patent 5,049,721 which is hereby incorporated by reference, in such a manner that the characters mask or hide the apertures. In addition, the apertures may be arrayed to produce a design, spell out a code, trademark or other symbol.

The number and size of the apertures is determined by the end use of the dosage form. For example, such apertures could be used to limit or enhance the delivery rate of the chemical to the environment of use.

In the pharmaceutical field, the dosage form may consist of a tablet or other drug delivery device. The drug delivery device may be coated or uncoated. Uncoated tablets may contain apertures in order to assure rapid disintegration of the tablet or to produce incursions which help in breaking the tablet. Coated tablets may contain apertures to assist in entry of fluid from environment of use, allow for passage of drug from the core of the tablet to the environment or to define the amount of core area exposed to the environment.

- 8 -

The dosage form may be a core which comprises a polymer which forms gelatinous microscopic particles upon hydration and a medicament, the core being completely coated with a water insoluble and water impermeable coating. This process for producing a plurality of apertures using a digital laser marking system may then be used to drill a predetermined number of apertures into the surface of the dosage form. If the dosage form has distinct faces, apertures may be drilled in all of the faces, either sequentially or simultaneously. In a system of this type, the apertures provide access to the solution which makes up the environment of use. The solution hydrates the polymer at the exposed surfaces. The polymer forms gelatinous microscopic particles which move from the tablet into the environment of use, carrying with them the active ingredient.

The preferred digital laser marking system has been previously described. This system is commercially available under the name DIGIMARK™. The seven carbon dioxide laser tubes can be individually pulsed and produce a 7 x n matrix on the dosage form. The length of time that the laser is pulsed is referred to as the pulse width. This time is measured in microseconds. The depth of each aperture is determined by the operational wattage, the characteristics of the dosage form surface, the velocity at which the dosage form travels through the laser stage and the pulse width. Pulse widths of from about 1 microsecond to about 10,000 microsecond may be useful in this process.

The cycle time between the pulses is referred to as the internal stroke time. This is the amount of time from the start of one pulse to the start of the next. As indicated earlier, internal stroke time and dosage form velocity determine the distance between the linear arrays of apertures. Internal stroke times of from about 1 microsecond to about 20,000 microsecond may be useful for generating apertures in dosage forms.

The energy developed by the laser may range from about 5 to about 1000 watts. The wavelength of a carbon dioxide laser is about 10.6 microns.

- 9 -

By "pulsing the digital laser marking system" is meant that a signal is sent to any or all of the lasers to energize the laser beam. The pulse width may vary from about 1 usec to about 10,000 microseconds:

5 When the pulse width is relatively short and the dosage form velocity through the laser stage is relatively slow, a more circular aperture will result. The diameter of the apertures contemplated by this invention ranges from about 100 μm to about 2000 μm . If the pulse
10 width is relatively long and the dosage form velocity through the laser stage relatively fast, a more oval shaped aperture results. The length of the oval shaped aperture may extend from one end of the dosage form to the other. However, in general, the length ranges from about 20
15 microns to about 1 cm. The width of the oval shaped apertures ranges from about 20 microns to about 2000 microns.

20 The dosage form may be moved onto the laser stage by any conventional or non-conventional means, including manual incursion and removal. In practice, a conveyer system may be employed to move up to about 100,000 dosage forms per hour through the laser stage. The dosage form may be moved to the laser stage quickly and then
25 more slowly move across the stage to produce the desired array of apertures. Further, the dosage form may be rotated, inverted or otherwise maneuvered to allow for the production of apertures on all sides of the dosage form.

30 In another embodiment of this technology, the laser beams may be split using mirrors or other optical devices so that more than one side of the dosage form may be drilled simultaneously.

EXAMPLES

EXAMPLE 1

Tablets cores containing lovastatin, CARBOPOL® 974P, trisodium citrate and lactose in ratios of 3:2:2:2 were prepared by compression using 1/4 inch standard concave punches. The tablets were

- 10 -

coated to a thickness of 100 microns with a coating composition comprising cellulose acetate butyrate and triethyl citrate, using a Freund® Model MCT-Mini H-Coater (8-inch pan).

5 Twenty-one apertures were drilled in each face of the coated tablets, as shown in Figure 2, using a DIGIMARK™ digital laser marking system at four pulse width settings of 1000, 1500, 2000 and 2500 micro seconds, at a surface feed rate of 15 feet per minutes. This feed rate corresponds to approximately 32,400 tablets per hour if the
10 tablets were arranged three to an inch and both faces of the tablet were drilled simultaneously. The approximate hole size, as measured by microscopic imaging using an Analytical Imaging Concepts IM4000, is reported in Table I.

As the results indicate, the hole size increased with an increase in the pulse width. The grid of holes was centered on the tablet
15 face and occupied an area less than half that of the tablet face. The distance between the rows and columns of holes was approximately one hole diameter.

In vitro release tests were carried out at 37°C using USP
20 Apparatus II in pH 7.4 phosphate buffer containing 0.4% sodium dodecyl sulfate at 50 rpm. The drug released was monitored by flow-through UV spectrophotometry. Tablets marked with all but the lowest pulse width (1000 microseconds) were observed to release lovastatin at a similar rate with no appreciable lag time.

25

30

- 11 -

TABLE I

Release Rate of Laser Marked (21 holes/face) Tablet

Cumulative Percent Lovastatin Released

Pulse Width	Hole size	5 hr	10 hr	15 hr
2500	396+/- 19 μ m	30, 28	56, 52	73, 70
2000	371 +/- 30 μ m	28, 27	53, 52	70, 70
1500	338 +/- 16 μ m	27	51	68
1000	316 +/- 6 μ m	15	32	48

EXAMPLE 2

Twenty-four (24) apertures of 0.35 mm in diameter were drilled in each face of the coated tablets prepared for the study in Example 1 using the DIGIMARK™ digital laser marking system. A 4 x 6 array was used with a pulse width of 2500 microseconds and an internal stroke of 5000 microseconds. The apertures were measured as in Example 1. Release rates were studied as in Example 1. The results are shown in Table II.

TABLE II

Release Rate of Laser Marked (24 holes/face) Tablets

Cumulative Percent Lovastatin Released

Hole Size	5 hr	10 hr	15 hr
0.35 mm	52.4 \pm 3.2	87.1 \pm 1.6	96.5 \pm 0.51

- 12 -

EXAMPLE 3

Forty-two (42) apertures of 0.45 mm in diameter were drilled in a single tablet face of the coated tablets of Example 1 using the DIGIMARK™ digital laser marking system. A 7 x 6 array was used with a pulse width of 4250 microseconds and an internal stroke of 8000 microseconds. Measurement of the aperture size and determination of release rates were as in Example 1. The results are shown in Table III.

TABLE III

Release Rate of Laser Marked (24 holes/face) Tablets

Cumulative Percent Lovastatin Released

Hole Size	5 hr	10 hr	15 hr
0.45 mm	44.7 \pm 0.4	72.55 \pm 1.1	82.6 \pm 0.6

- 13 -

WHAT IS CLAIMED IS:

1. A process for producing a dosage form having a plurality of apertures in its outside surface, using a digital laser marking system focused at a laser stage, the steps comprising:

- (a) moving the dosage form into the laser stage of the digital laser marking system;
- (b) pulsing the digital laser marking system to energize those laser tubes needed to drill the desired apertures along a linear array on the dosage form;
- (c) moving the dosage form on the laser stage and pulsing the digital laser marking system to produce an additional linear array of apertures as required;
- (d) removing the dosage form from the laser stage.

2. The process of Claim 1, wherein the apertures are arranged in the form of an m by n matrix to generate a desired pattern of apertures, where m and n range from 1 to about 1000.

3. The process of Claim 2, wherein the plurality of laser tubes can be energized individually or in parallel.

4. The process of Claim 3, wherein the dosage form is designed to deliver a chemical to an environment of use.

5. The process of Claim 4, wherein the dosage form is designed to deliver medicament to an animal.

6. The process of Claim 5, wherein the dosage form is designed to deliver medicament to a human.

7. The process of Claim 6, wherein the dosage form is selected from the group consisting of tablets, capsules, lozenges, boluses, pills, wafers, disks, expandable devices, patches, suppositories,

- 14 -

collars, pellets, controlled release devices, slow release devices and other medicament delivery devices.

5 8. The process of Claim 7, wherein the dosage form is a core covered with a water insoluble and water impermeable coating.

 9. The process of Claim 8, wherein the apertures are drilled through the film coating and terminate in the core of the dosage form.

10 10. The process of Claim 9, wherein the apertures extend completely through the dosage form.


15

20

25

30

Figure 1



SUBSTITUTE SHEET

Figure 3




Figure 5




Figure 2





Figure 4



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/06197

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :B23K 26/00

US CL :219/12.71

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 219/12.7, 121.82

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS Text: Laser, Perforation, dosagelorm, drill? Capsule

APS Image

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 3,620,759 (MADDOX) 16 November 1971, see entire document.	---
A	US, A, 3,823,816 (CONTROULIS, ET AL.) 16 July 1974, see entire document.	---
Y	US, A, 4,063,064 (SAUNDERS, ET AL.) 13 December 1977, see entire document.	1-21
Y	US, A, 4,088,864 (THEEUWES, ET AL.) 09 May 1978, see entire document.	1-21
X	US, A, 4,524,785 (SERAGNOLI, ET AL.) 25 June 1985, see entire document.	1-7,20,21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be part of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 AUGUST 1993

Date of mailing of the international search report

08 OCT 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

CLARENCE ALBRITTON

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1709

Form PCT/ISA/210 (second sheet)(July 1992)*